Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484821 | 0.90 | — | — | |
| SCHEMBL4484818 | 0.90 | — | — | |
| SCHEMBL6128453 | 0.82 | — | — | |
| SCHEMBL5496289 | 0.78 | DUT (0.31) | DUT | |
| SCHEMBL17005990 | 0.78 | DUT (0.31) | DUT | |
| SCHEMBL18244588 | 0.76 | LPAR2 (0.31) | DUT | |
| SCHEMBL6389772 | 0.76 | DUT (0.30) | DUT | |
| SCHEMBL18245124 | 0.76 | LPAR2 (0.31) | DUT | |
| SCHEMBL6389768 | 0.76 | DUT (0.30) | DUT | |
| SCHEMBL17997131 | 0.76 | LPAR2 (0.31) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207936-A1 | Chemical intermediate for drugs; reduction of the corresponding 3-hydroxybutyrate ; then oxidation using nitroxyl compound and co-oxidizer | KANEKA CORPORATION (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1862465-A1 | METHOD OF PRODUCING 3-HYDROXYBUTYRALDEHYDE DERIVATIVE | Kaneka Corporation (JP) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207936-A1 | Chemical intermediate for drugs; reduction of the corresponding 3-hydroxybutyrate ; then oxidation using nitroxyl compound and co-oxidizer | CYP11B2, CYP11B1, ADH5 | DUT 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.